Although some studies reported variable sensitivity and specificity for this technique, a meta-analysis of melanoma and other BRAF-mutated cancers demonstrated that the pooled sensitivity for HRM in melanoma was ~99% (ranging from 93% to 100%) and pooled specificity was ~99% (ranging from 88% to 100%) [60]. Here, BRAF is linked to melanoma.